Clinical Trials
Elacestrant plus everolimus shows benefit in advanced breast cancer trial
Rugo et alClin Cancer Res

Findings from the Phase 1b/2 ELEVATE umbrella trial demonstrate clinical activity and safety for the all-oral combination of elacestrant, an oral selective estrogen receptor degrader (SERD), plus everolimus in patients with estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced breast cancer (ABC). Enrolled patients had disease progression on 1 to 2 prior lines of endocrine therapy combined with a CDK4/6 inhibitor and no prior chemotherapy for advanced disease. In the Phase 1b portion (n=23), the recommended Phase 2 dose (RP2D) was identified as elacestrant 345 mg daily combined with everolimus 7.5 mg daily.
The Phase 2 cohort (n=50) evaluated patients with high-risk clinical and genomic features, including 72% with visceral metastases, 50% with prior fulvestrant exposure, 20% with primary endocrine resistance, 42% harboring ESR1 mutations, and 50% harboring PIK3CA mutations. Treatment with the combination yielded a median progression-free survival (PFS) of 8.3 months (95% CI: 4.0–10.2) in the overall population. Subgroup analyses demonstrated prolonged PFS across molecular subtypes, showing 8.3 months (95% CI: 3.5–12.9) in ESR1-mutated tumors, 9.0 months (95% CI: 4.2–12.7) in ESR1 wild-type tumors, 8.3 months (95% CI: 3.6–10.2) in PIK3CA-mutated tumors, and 9.4 months (95% CI: 4.0–NR) in PIK3CA wild-type tumors. Adverse events were predominantly grade 1 or 2 and aligned with the established safety profiles of everolimus plus standard endocrine therapy. Treatment discontinuation due to adverse events occurred in 6% of patients, and dose reductions were required in 2%. These results support elacestrant as an effective endocrine backbone for combination targeted therapies targeting the PI3K/AKT/mTOR pathway in pretreated ER+/HER2- advanced breast cancer.
Key Takeaways
- In the Phase 2 ELEVATE trial cohort, elacestrant 345 mg plus everolimus 7.5 mg achieved a median progression-free survival of 8.3 months overall in patients with pretreated ER+/HER2- advanced breast cancer, with consistent outcomes in ESR1-mutated (8.3 months) and ESR1 wild-type (9.0 months) subgroups.
- Progression-free survival benefit was maintained regardless of PIK3CA status, demonstrating a median PFS of 8.3 months in PIK3CA-mutated and 9.4 months in PIK3CA wild-type tumors.
- The combination safety profile was consistent with known everolimus toxicity, consisting mostly of grade 1-2 adverse events, with overall treatment discontinuation and dose reduction rates of 6% and 2%, respectively.
Read the original sourceClin Cancer Res
